"At Excel Diagnostics & Nuclear Oncology Center, we offer state of the art imaging technology and highly sophisticated systems to provide the full range of imaging services, including: PET/CT Scan, MRI, CT (CT64), Nuclear Medicine, Ultrasound, Digital Mammography, X-Ray, and Bone Mineral Density imaging. All our modalities are accredited by the American College of Radiology (ACR)."

During the past decade, Excel Diagnostics and Nuclear Oncology Center conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 5 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 3 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Excel Diagnostics and Nuclear Oncology Center" #1 sponsor was "Radiomedix, Inc." with 3 trials, followed by "Endocyte" with 2 trials sponsored, "Excel Diagnostics and Nuclear Oncology Center" with 2 trials sponsored, "ABX advanced biochemical compounds GmbH" with 1 trials sponsored and "Advanced Accelerator Applications" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Excel Diagnostics and Nuclear Oncology Center" #1 collaborator was "Orano Med LLC" with 2 trials as a collaborator, "ABX CRO" with 1 trials as a collaborator, "Excel Diagnostics and Nuclear Oncology Center" with 1 trials as a collaborator and "PSI CRO" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Excel Diagnostics and Nuclear Oncology Center" are "Neuroendocrine Tumors" (5 trials), "Metastatic Castration Resistant Prostate Cancer" (2 trials), "Prostate Cancer" (2 trials), "Carcinoid Tumor of the Small Bowel" (1 trials) and "Coronary Artery Disease" (1 trials). Many other conditions were trialed in "Excel Diagnostics and Nuclear Oncology Center" in a lesser frequency.

Most popular intervention types in "Excel Diagnostics and Nuclear Oncology Center" are "Drug" (14 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "177Lu-PSMA-617" (2 trials), "AlphaMedix" (2 trials), "177Lu-DOTA0-Tyr3-Octreotate" (1 trials), "177Lu-DOTATATE" (1 trials) and "177Lu-DOTATOC" (1 trials). Other intervention names were less common.

The vast majority of trials in "Excel Diagnostics and Nuclear Oncology Center" are 8 trials for "All" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Excel Diagnostics and Nuclear Oncology Center". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Excel Diagnostics and Nuclear Oncology Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Excel Diagnostics and Nuclear Oncology Center, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".